Abstract
The noradrenergic system has been evaluated in numerous animal studies (Arnsten, 2020). Agents that target the norepinephrine system are promising treatment targets and may ameliorate cognitive impairments in individuals with schizophrenia and schizotypal personality disorder (SPD), a group with cognitive impairments similar to those seen in schizophrenia, but which is psychoactive drug naïve, eliminating medication confounds associated with schizophrenia research. We evaluated the efficacy of guanfacine, an α2a agonist, in SPD.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
